Guidance

Candidozyma auris: guidance for acute healthcare settings

Candidozyma auris (C.auris): laboratory investigation, management and infection prevention and control of cases.

• From: UK Health Security Agency
• Published: 27 June 2016
• Last updated: 21 August 2025
  Show all updates

  1. 21 August 2025

     Added C. auris name change notice.

  2. 19 March 2025

     Updated guidance and added summary.

  3. 11 August 2017

     Updated version of guidance for laboratories, healthcare providers and healthcare professionals replaces that first published in 2016.

  4. 27 June 2016

     First published.

Documents

Summary of recommendations

HTML

Introduction and background

HTML

Investigation in clinical laboratories

HTML

Screening of patients and contacts

HTML

Management of patients who test positive for C. auris (colonised or infected)

HTML

Infection prevention and control (IPC)

HTML

Notification, reporting and information sharing

HTML

Acknowledgements

HTML

References

HTML

Details

The yeast formerly known as Candida auris has been reclassified as Candidozyma auris following a taxonomic revision in 2023.

Candidozyma auris (C. auris) is a rapidly emerging fungal pathogen with a global distribution. Designated a critical priority fungal pathogen by the World Health Organization in 2022, C. auris can result in colonisations, severe invasive infections and outbreaks within healthcare settings. Resistance has developed to many available classes of antifungals, including the first-line antifungal agent fluconazole, with the emergence of pan-resistant strains. In non-UK settings, invasive disease has been associated with significant mortality.

This guidance outlines recommendations for the laboratory investigation, management, and infection prevention and control practices associated with C. auris in healthcare settings.

This update supersedes the previous guidance, released in 2017.